Safety of Adalimumab in patients with Crohn's Disease: Analysis of global clinical trials

被引：0
作者：
Colombel, J. [1 ]
Pannaccione, R. [2 ]
Sandbom, W. [3 ]
Rutgeerts, P. [4 ]
Hanauer, S. [5 ]
Reinisch, W. [6 ]
Pollack, P. [7 ]
Kent, J. [8 ]
Cardoso, A. [8 ]
Lau, W. [7 ]
机构：
[1] Ctr Hosp Univ Lille, Hop Claude Huriez, Lille, France
[2] Univ Calgary, Dept Med, Calgary, AB, Canada
[3] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[5] Univ Chicago, Chicago, IL 60637 USA
[6] Med Univ Vienna, Vienna, Austria
[7] Abbott Labs, Parsippany, NJ USA
[8] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
INFLAMMATORY BOWEL DISEASES | 2008年 / 14卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 50 条
  • [41] Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies
    Edouard J. Louis
    Walter Reinisch
    David A. Schwartz
    Robert Löfberg
    Anne M. Robinson
    Sofie Berg
    Anthony W. Wang
    Jen-fue Maa
    Bidan Huang
    Brandee Pappalardo
    Advances in Therapy, 2018, 35 : 563 - 576
  • [42] Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: Results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial
    Panaccione, Remo
    Loftus, Edward V., Jr.
    Binion, David
    McHugh, Kevin
    Alam, Shamsul
    Chen, Naijun
    Guerette, Benoit
    Mulani, Parvez
    Chao, Jingdong
    CANADIAN JOURNAL OF GASTROENTEROLOGY, 2011, 25 (08): : 419 - 425
  • [43] Clinical Experience with Adalimumab in a Multicenter Swiss Cohort of Patients with Crohn's Disease
    Nichita, Cristina
    Stelle, Marc
    Vavricka, Stephan R.
    El-Wafa, Ali Abdou
    De Saussure, Philippe
    Straumann, Alex
    Rogler, Gerhard
    Michetti, Pierre F.
    GASTROENTEROLOGY, 2009, 136 (05) : A681 - A681
  • [44] Real-World Efficacy And Safety Of Ustekinumab And Adalimumab In Patients With Crohn's Disease: Propensity Matched Analysis
    Shin, Y.
    Hong, S. N.
    Kim, E. R.
    Chang, D. K.
    Kim, Y. H.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 842 - 842
  • [45] Adalimumab in Crohn's disease
    Van Assche, Gert
    Vermeire, Severine
    Rutgeerts, Paul
    BIOLOGICS-TARGETS & THERAPY, 2007, 1 (04) : 355 - 365
  • [46] Adalimumab for Crohn's disease
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (04): : 291 - 291
  • [47] Adalimumab in Steroid-Dependent Crohn's Disease Patients: Analisys of Efficacy, Prognostic Factors for Clinical Benefit and Safety
    Orlando, Ambrogio
    Renna, Sara
    Mocciaro, Filippo
    Cappello, Maria
    Di Mitri, Roberto
    Randazzo, Claudia
    Cottone, Mario
    GASTROENTEROLOGY, 2011, 140 (05) : S445 - S445
  • [48] Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.
    Schiff, MH
    Burmester, GR
    Pangan, AL
    Kupper, H
    Spencer-Green, GT
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S562 - S562
  • [49] Adalimumab - In Crohn's disease
    Plosker, Greg L.
    Lyseng-Williamson, Katherine A.
    BIODRUGS, 2007, 21 (02) : 125 - 132
  • [50] ADALIMUMAB IN STEROID-DEPENDENT CROHN'S DISEASE PATIENTS: ANALISYS OF EFFICACY, PROGNOSTIC FACTORS FOR CLINICAL BENEFIT AND SAFETY
    Orlando, A.
    Renna, S.
    Mocciaro, F.
    Cappello, M.
    Di Mitri, R.
    Randazzo, C.
    Cottone, M.
    DIGESTIVE AND LIVER DISEASE, 2011, 43 : S134 - S134
12345